Case Reports
Early Access
https://doi.org/10.4081/dr.2026.10366

Omalizumab for treatment of refractory urticaria in a patient with metastatic uveal melanoma receiving tebentafusp

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 6 May 2026
0
Views
0
Downloads
Uveal melanoma, omalizumab, tebentafusp

Authors

Faith Simmonds
Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States.
Veronica Kashua
Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Diana McDonnell
Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Mariam El-Ashmawy
Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States.
Alexandra J. Coromilas
ajc2154@cumc.columbia.edu
Department of Dermatology, Columbia University Irving Medical Center, New York, NY, United States.

Tebentafusp is an immune-mobilizing monoclonal T-cell receptor approved for the treatment of metastatic uveal melanoma. While this agent improves outcomes in patients with unresectable or metastatic uveal melanoma, tebentafusp commonly results in dermatologic cutaneous toxicities. Herein, we present a case of a 32-year-old patient diagnosed with juxtapapillary choroidal melanoma of the left eye with metastases to the liver who developed a diffuse urticarial skin reaction to tebentafusp that was successfully treated with omalizumab.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021;385:1196-206.
2. U.S. Food and Drug Administration. KIMMTRAK® (tebentafusp-tebn) injection: prescribing information. U.S. Food and Drug Administration; 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761228s003lbl.pdf
3. Hassel JC, Stanhope S, Greenshields-Watson A, et al. Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. J Invest Dermatol 2025;145:559-72.e9.
4. Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021;32:736-45.
5. Kuo AMS, Gu S, Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer 2023;11:e007324.

How to Cite



1.
Simmonds F, Kashua V, McDonnell D, El-Ashmawy M, Coromilas AJ. Omalizumab for treatment of refractory urticaria in a patient with metastatic uveal melanoma receiving tebentafusp. Dermatol Reports [Internet]. 2026 May 6 [cited 2026 May 6];. Available from: https://journals.pagepress.net/dr/article/view/10366
Copyright (c) 2026 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.